These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 34777340)

  • 1. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
    Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
    Front Immunol; 2021; 12():716317. PubMed ID: 34777340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
    Derosa L; Hellmann MD; Spaziano M; Halpenny D; Fidelle M; Rizvi H; Long N; Plodkowski AJ; Arbour KC; Chaft JE; Rouche JA; Zitvogel L; Zalcman G; Albiges L; Escudier B; Routy B
    Ann Oncol; 2018 Jun; 29(6):1437-1444. PubMed ID: 29617710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials.
    Chalabi M; Cardona A; Nagarkar DR; Dhawahir Scala A; Gandara DR; Rittmeyer A; Albert ML; Powles T; Kok M; Herrera FG;
    Ann Oncol; 2020 Apr; 31(4):525-531. PubMed ID: 32115349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (AB-CLICaP).
    Ruiz-Patiño A; Barrón F; Cardona AF; Corrales L; Mas L; Martín C; Zatarain-Barrón ZL; Recondo G; Ricaurte L; Rojas L; Archila P; Rodríguez J; Sotelo C; Viola L; Vargas C; Carranza H; Otero J; Pino LE; Rolfo C; Rosell R; Arrieta O;
    Thorac Cancer; 2020 Sep; 11(9):2552-2560. PubMed ID: 32705787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
    Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive impact of antibiotics in patients with advanced non small-cell lung cancer receiving immune checkpoint inhibitors : Antibiotics immune checkpoint inhibitors in advanced NSCLC.
    Schett A; Rothschild SI; Curioni-Fontecedro A; Krähenbühl S; Früh M; Schmid S; Driessen C; Joerger M
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):121-131. PubMed ID: 31745593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
    Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
    JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
    Front Immunol; 2022; 13():968729. PubMed ID: 35967438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients.
    Peng K; Chen K; Teply BA; Yee GC; Farazi PA; Lyden ER
    Ann Pharmacother; 2022 Apr; 56(4):377-386. PubMed ID: 34282636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    Rounis K; Makrakis D; Papadaki C; Monastirioti A; Vamvakas L; Kalbakis K; Gourlia K; Xanthopoulos I; Tsamardinos I; Mavroudis D; Agelaki S
    PLoS One; 2021; 16(6):e0252537. PubMed ID: 34061904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150.
    Hopkins AM; Kichenadasse G; McKinnon RA; Abuhelwa AY; Logan JM; Badaoui S; Karapetis CS; Rowland A; Sorich MJ
    Br J Cancer; 2022 Jan; 126(1):42-47. PubMed ID: 34711947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.
    Kartolo A; Feilotter H; Hopman W; Fung AS; Robinson A
    Cancer Treat Res Commun; 2021; 27():100330. PubMed ID: 33581492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer.
    Iglesias-Santamaría A
    Clin Transl Oncol; 2020 Sep; 22(9):1481-1490. PubMed ID: 31919759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study.
    Boudou-Rouquette P; Arrondeau J; Gervais C; Durand JP; Fabre E; De Percin S; Villeminey CV; Piketty AC; Rassy N; Ulmann G; Damotte D; Mansuet-Lupo A; Giraud F; Alifano M; Wislez M; Alexandre J; Jouinot A; Goldwasser F
    EBioMedicine; 2021 Nov; 73():103630. PubMed ID: 34688030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors.
    Baek YH; Kang EJ; Hong S; Park S; Kim JH; Shin JY
    Int J Cancer; 2022 Apr; 150(8):1291-1300. PubMed ID: 34877670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association between proton pump inhibitors use and clinical outcome of patients receiving immune checkpoint inhibitors therapy.
    Li M; Zeng C; Yao J; Ge Y; An G
    Int Immunopharmacol; 2020 Nov; 88():106972. PubMed ID: 33182025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.